Amy K. Dickey

493 total citations
28 papers, 271 citations indexed

About

Amy K. Dickey is a scholar working on Molecular Biology, Pediatrics, Perinatology and Child Health and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Amy K. Dickey has authored 28 papers receiving a total of 271 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 8 papers in Pediatrics, Perinatology and Child Health and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Amy K. Dickey's work include Porphyrin Metabolism and Disorders (21 papers), Heme Oxygenase-1 and Carbon Monoxide (15 papers) and Neonatal Health and Biochemistry (8 papers). Amy K. Dickey is often cited by papers focused on Porphyrin Metabolism and Disorders (21 papers), Heme Oxygenase-1 and Carbon Monoxide (15 papers) and Neonatal Health and Biochemistry (8 papers). Amy K. Dickey collaborates with scholars based in United States, Germany and Norway. Amy K. Dickey's co-authors include Dennis E. Hallahan, Dinesh Thotala, Rebecca Karp Leaf, Eugenia M. Yazlovitskaya, Ling Geng, K. Leahy, Stephen M. Schleicher, Rong Hu, Manisha Balwani and Gregory H. Babunovic and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Blood.

In The Last Decade

Amy K. Dickey

23 papers receiving 266 citations

Peers

Countries citing papers authored by Amy K. Dickey

Since Specialization

Citations

This map shows the geographic impact of Amy K. Dickey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy K. Dickey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy K. Dickey more than expected).

Fields of papers citing papers by Amy K. Dickey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy K. Dickey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy K. Dickey. The network helps show where Amy K. Dickey may publish in the future.

Co-authorship network of co-authors of Amy K. Dickey

This figure shows the co-authorship network connecting the top 25 collaborators of Amy K. Dickey. A scholar is included among the top collaborators of Amy K. Dickey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy K. Dickey. Amy K. Dickey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The GLYT1 inhibitor bitopertin mitigates erythroid PPIX production and liver disease in erythroid protoporphyria 2025 ·Journal of Clinical Investigation ·Sarah Ducamp, Min Wu, Juan Putra, Dean R. Campagna, (unknown), (unknown), Matthew M. Heeney, Amy K. Dickey, Rebecca Karp Leaf, Mark D. Fleming, Brian MacDonald, Paul J. Schmidt	1
2	Impact of delay in diagnosis in patients with erythropoietic protoporphyria: A cross-sectional survey study 2025 ·JAAD International ·(unknown), (unknown), (unknown), (unknown), Sarina B. Elmariah, Karl E. Anderson, Rebecca Karp Leaf, Hetanshi Naik, Amy K. Dickey	0
3	Bitopertin shows efficacy in patients with erythropoietic protoporphyria: Results from the randomized, double-blind, placebo-controlled AURORA trial 2025 ·Journal of the American Academy of Dermatology ·Amy K. Dickey, Herbert L. Bonkovsky, Manisha Balwani, Karl E. Anderson, Cynthia Levy, Manish Thapar, Bruce Wang, Melanie Chin, (unknown), Robert J. Desnick, Sioḃán Keel	0
4	Givosiran: a targeted treatment for acute intermittent porphyria 2024 ·Hematology ·Amy K. Dickey, Rebecca Karp Leaf	5
5	Afamelanotide for Treatment of the Protoporphyrias: Impact on Quality of Life and Laboratory Parameters in a US Cohort 2024 ·Life ·Rebecca Karp Leaf, Hetanshi Naik, (unknown), Sarina B. Elmariah, (unknown), Jennifer Mead, John Trinidad, Behnam Saberi, (unknown), (unknown), (unknown), David E. Leaf, Karl E. Anderson, Amy K. Dickey	2
6	Results from the Aurora Study: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin in Erythropoietic Protoporphyria 2024 ·Blood ·Amy K. Dickey, Sioḃán Keel, Herbert L. Bonkovsky, Karl E. Anderson, Manisha Balwani, Cynthia Levy, Manish Thapar, Bruce Wang, Brendan M. McGuire, (unknown)	1
7	Porphyria cutanea tarda: a unique iron-related disorder 2024 ·Hematology ·Rebecca Karp Leaf, Amy K. Dickey	0
8	Diagnosis and management of protoporphyria-related liver dysfunction in erythropoietic protoporphyria and x-linked protoporphyria: A patient-friendly summary of the 2023 evidence-based consensus guidelines 2024 ·Clinical Liver Disease ·(unknown), (unknown), (unknown), Amy K. Dickey, Cynthia Levy	0
9	Tobacco smoke exposure recruits inflammatory airspace monocytes that establish permissive lung niches for Mycobacterium tuberculosis 2023 ·Science Translational Medicine ·Björn Corleis, Constantine N. Tzouanas, Marc H. Wadsworth, (unknown), (unknown), Abigail E. Schiff, (unknown), (unknown), Anca Dorhoi, Amy K. Dickey, Benjamin D. Medoff, Alex K. Shalek, Douglas S. Kwon	11
10	PB2562: STUDY DESIGN OF THE AURORA TRIAL: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF BITOPERTIN IN ERYTHROPOIETIC PROTOPORPHYRIA 2023 ·HemaSphere ·Cynthia Levy, Karl E. Anderson, Manisha Balwani, Herbert L. Bonkovsky, Amy K. Dickey, Sioḃán Keel, Brendan M. McGuire, Roy E. Smith, Manish Thapar, Bruce Wang, William Savage	1
11	How I treat erythropoietic protoporphyria and X-linked protoporphyria 2023 ·Blood ·Rebecca Karp Leaf, Amy K. Dickey	10
12	Light-Related Cutaneous Symptoms of Erythropoietic Protoporphyria and Associations With Light Sensitivity Measurements 2023 ·JAMA Dermatology ·(unknown), (unknown), Rebecca Karp Leaf, (unknown), (unknown), (unknown), Karl E. Anderson, (unknown), Irene E. Kochevar, Sarina B. Elmariah, Amy K. Dickey	6
13	Prospective observational pilot study of quantitative light dosimetry in erythropoietic protoporphyria 2022 ·Journal of the American Academy of Dermatology ·Amy K. Dickey, (unknown), (unknown), Rebecca Karp Leaf, Sarina B. Elmariah, Hetanshi Naik, Karl E. Anderson, Jared Conley, Christiana Iyasere, Sophia Zhao, Judith Birkenfeld, (unknown), (unknown), Sarah Ducamp, David C. Christiani, Mark D. Fleming, Irene E. Kochevar	6
14	Quantifying the impact of symptomatic acute hepatic porphyria on well‐being via patient‐reported outcomes: Results from the Porphyria Worldwide Patient Experience Research (POWER) study 2022 ·JIMD Reports ·Amy K. Dickey, (unknown), (unknown), (unknown), (unknown), Rocco Falchetto, (unknown), Jasmin Barman‐Aksözen, (unknown), (unknown), Joana Matos, (unknown), (unknown), John J. Ko, (unknown), (unknown), (unknown)	14
15	Smoking and Human Immunodeficiency Virus 1 Infection Promote Retention of CD8+ T Cells in the Airway Mucosa 2021 ·American Journal of Respiratory Cell and Molecular Biology ·Björn Corleis, (unknown), (unknown), (unknown), Amy K. Dickey, (unknown), Abigail E. Schiff, Musie Ghebremichael, Puja Kohli, Tilo Winkler, (unknown), Benjamin D. Medoff, Douglas S. Kwon	12
16	T cell-tropic HIV efficiently infects alveolar macrophages through contact with infected CD4+ T cells 2021 ·Scientific Reports ·Abigail E. Schiff, (unknown), (unknown), (unknown), Martin J. Deymier, Thomas Diefenbach, Amy K. Dickey, Athe Tsibris, Alejandro B. Balazs, (unknown), Benjamin D. Medoff, Gerhard Walzl, Robert J. Wilkinson, Wendy A. Burgers, Björn Corleis, Douglas S. Kwon	25
17	Evidence in the UK Biobank for the underdiagnosis of erythropoietic protoporphyria 2020 ·Genetics in Medicine ·Amy K. Dickey, Corbin Quick, Sarah Ducamp, Zhaozhong Zhu, (unknown), Hetanshi Naik, Manisha Balwani, Karl E. Anderson, Xihong Lin, John E. Phillips, (unknown), Herbert L. Bonkovsky, Brendan M. McGuire, Bruce Wang, Daniel I. Chasman, Jordan W. Smoller, Mark D. Fleming, David C. Christiani	22
18	Flagellin-independent effects of a Toll-like receptor 5 polymorphism in the inflammatory response to Burkholderia pseudomallei 2019 ·PLoS neglected tropical diseases ·Amy K. Dickey, Narisara Chantratita, Sarunporn Tandhavanant, (unknown), (unknown), (unknown), (unknown), (unknown), Sandra Schwarz, Mark M. Wurfel, Susanna Kosamo, T. Eoin West	8
19	A New Class of Molecular Targeted Radioprotectors: GSK-3β Inhibitors 2010 ·International Journal of Radiation OncologyBiologyPhysics ·Dinesh Thotala, Ling Geng, Amy K. Dickey, Dennis E. Hallahan, Eugenia M. Yazlovitskaya	51
20	GSK-3β inhibition promotes cell death, apoptosis, and in vivo tumor growth delay in neuroblastoma Neuro-2A cell line 2010 ·Journal of Neuro-Oncology ·Amy K. Dickey, Stephen M. Schleicher, K. Leahy, Rong Hu, Dennis E. Hallahan, Dinesh Thotala	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact